Printer Friendly

FDA APPROVES ddC

 FDA APPROVES ddC
 WASHINGTON, June 22 /PRNewswire/ -- HHS Secretary Louis W.


Sullivan, M.D., today announced that the Food and Drug Administration has approved the AIDS drug zalcitabine, commonly known as ddC. It is the third drug licensed specifically for use in treating the human immunodeficiency virus, the cause of AIDS.
 Zalcitabine was approved for use in combination with the first approved AIDS drug, zidovudine -- or AZT -- as a treatment option for adult patients with advanced HIV infection who show signs of clinical or immunological deterioration.
 "This drug approval represents another step forward for patients with AIDS," Sullivan said. "Zalcitabine has been rapidly developed, tested and reviewed through the cooperative efforts of scientists in the National Institutes of Health and FDA, academia and the pharmaceutical industry.
 Early clinical trial data have shown that increases in CD4 cells (immune cells) were somewhat greater and more sustained in patients treated with the combination of zalcitabine and zidovudine than in those who received zidovudine alone as initial therapy. An increase in CD4 cells is believed to indicate that the body's disease-fighting capability has been at least transiently enhanced.
 At present, however, there are no study results demonstrating enhanced survival, lowered incidence of opportunistic infections or decreased progression of HIV infection for patients treated with the combination of zidovudine and ddC.
 DDC is the first drug approved under the principles and procedures of FDA's proposed accelerated drug review policy, endorsed by the White House Council on Competitiveness and announced by the vice president on April 9. The proposal also provides for prompt removal of the drug from the market if further review determines the therapy to be ineffective.
 Four studies investigation the clinical usefulness of zalcitabine are continuing, to verify the clinical benefit of the combination therapy.
 "This new drug is not a cure," said James Mason, M.D., assistant secretary for health and head of the Public Health Service, "but it constitutes an important addition to the expanding group of antiviral drugs currently available, including AZT and DDI, for treating people with AIDS."
 The most severe side effects observed in individuals taking zalcitabine have been in the form of neurological complications, sometimes causing tingling and pain in the hands and feet. In controlled clinical studies, 10 to 12 percent of patients discontinued treatment because of these complications. Other side effects included pancreatitis (inflammation of the pancreas), rash, oral ulcers, decreased blood platelet (blood clotting elements) counts and abnormal liver function. The side effects of the combination of zalcitabine and zidovudine are about the same as those that would be anticipated with either drug, each with significant side effects alone.
 "This approval marks an important change in FDA's drug review policy," said
FDA Commissioner David A. Kessler, M.D. "In this way we can approve drugs that are both safe and effective as quickly as possible."
 The pharmacological action of zalcitabine, a chemically synthesized compound originally discovered for its antiviral activity by scientists at the National Institutes of Health in Bethesda, Md., appears to be its ability to prevent the AIDS virus from replicating or reproducing before T-cells (immune cells) are infected, thus preserving the cells' immune function.
 The drug, manufactured and distributed by Hoffmann La Roche of Nutley, N.J., is administered orally every eight hours in combination with AZT. Sold under the trade name HIVID, it is expected to be commercially available immediately.
 Both FDA and NIH are Public Health Service agencies within HHS.
 -0- 6/22/92
 /NOTE: Attention TV broadcasters: Please use open caption for the hearing impaired./
 /CONTACT: Faye Peterson of the Food and Drug Administration, 301-443-3285 or after hours, 301-916-1364/ CO: Food and Drug Administration ST: District of Columbia IN: MTC SU:


DC -- DC019 -- 2432 06/22/92 13:23 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1992
Words:623
Previous Article:MK WINS CONTRACT FOR DECOMMISSIONING OF RESEARCH REACTOR IN MASSACHUSETTS; RECEIVES LOCOMOTIVE AWARD IN AUSTRALIA
Next Article:FLUOR DANIEL AND DAVY MCKEE AWARDED KENNECOTT UTAH COPPER CORP.'S SMELTER MODERNIZATION PROJECT
Topics:


Related Articles
FIRST COMBINATION REGIMEN OF HIV DRUGS CLEARED BY FDA
MS DRUG LICENSED BY FDA
BRISTOL-MYERS SQUIBB FILES NEW DRUG APPLICATION FOR ANTI-AIDS DRUG ZERIT (STAVUDINE, d4T)
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL FOR FIRST IN NEW CLASS OF AIDS THERAPIES
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL FOR FIRST IN NEW CLASS OF AIDS THERAPIES
BOEHRINGER INGELHEIM FILES NEW DRUG APPLICATION FOR AIDS THERAPY VIRAMUNE(R)
FDA COMMITTEE RECOMMENDS FULL MARKETING CLEARANCE FOR HIVID(R) COMBINATION THERAPY
FDA COMMITTEE RECOMMENDS FULL MARKETING CLEARANCE FOR HIVID(R) COMBINATION THERAPY
ROCHE BEGINS FIRST 'PROTEASE-PROTEASE' COMBINATION STUDY WITH ITS AIDS DRUG INVIRASE AND ABBOTT'S NORVIR
Manufacturers may promote off-label uses for drugs.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters